Publications

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis
Corrias Mv, Parodi S, Tchirkov A, Lammens T, Vicha A, Pasqualini C, et al
Pediatric blood & cancer 2018;65(7):e27052-

MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling
Dzieran J, Rodriguez Garcia A, Westermark Uk, Henley Ab, Eyre Sánchez E, Träger C, et al
Proceedings of the National Academy of Sciences of the United States of America 2018;115(6):E1229-E1238

Emergence of new ALK mutations at relapse of neuroblastoma
Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, et al
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014;32(25):2727-34

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation
Cetinkaya C, Martinsson T, Sandgren J, Träger C, Kogner P, Dumanski J, et al
BMC cancer 2013;13():231-

Hepatoblastoma in the Nordic countries
Licht Sd, Schmidt Ls, Rod Nh, Schmiegelow K, Lahteenmaki Pm, Kogner P, et al
INTERNATIONAL JOURNAL OF CANCER 2012;131(4):E555-61

Incidence of Childhood Central Nervous System Tumors in the Nordic Countries
Schmidt Ls, Schmiegelow K, Lahteenmaki P, Trager C, Stokland T, Grell K, et al
PEDIATRIC BLOOD & CANCER 2011;56(1):65-9

AGE-DEPENDENT GENOTYPES IN HIGH-RISK NEUROBLASTOMA: MYCN AMPLIFICATION IS A FAST TRACK TO AGGRESSIVE DISEASE WHEREAS SEGMENTAL DELETION OF 11Q IMPLIES A MORE COMPLEX, MULTI-STEP TUMOR EVOLUTION
Hedborg F, Cetinkaya C, Martinsson T, Kogner P, Dumanski J, Trager C, et al
PEDIATRIC BLOOD & CANCER 2010;55(5):896-896

DIFFERENCES IN BIOLOGICAL FEATURES AND SURVIVAL IMPROVEMENT BETWEEN GENETIC SUBSETS OF HIGH-RISK NEUROBLASTOMA INDICATE THE NEED OF ADAPTED TREATMENT
Trager C, Vernby A, Caren H, Kryh H, Martinsson T, Hedborg F, et al
PEDIATRIC BLOOD & CANCER 2010;55(5):897-897

Fetal Growth, Preterm Birth, Neonatal Stress and Risk for CNS Tumors in Children: A Nordic Population- and Register-Based Case-Control Study
Schmidt Ls, Schuz J, Lahteenmaki P, Trager C, Stokland T, Gustafson G, et al
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 2010;19(4):1042-52

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset
Caren H, Kryh H, Nethander M, Sjoberg Rm, Trager C, Nilsson S, et al
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010;107(9):4323-8

Infectious exposure in the first years of life and risk of central nervous system tumours in children: analysis of birth order, childcare attendance and seasonality of birth
Schmidt Ls, Kamper-jorgensen M, Schmiegelow K, Johansen C, Lahteenmaki P, Trager C, et al
BRITISH JOURNAL OF CANCER 2010;102(11):1670-5

NEUROBLASTOMA INCIDENCE WAS STABLE BUT DIFFERENT FOR BOYS AND GIRLS OVER 27 YEARS IN SWEDEN WHILE NEUROBLASTOMA PROGNOSIS IMPROVED, IN PARTICULAR FOR HIGH-RISK DISEASE
Trager C, Kogner P, Vernby A, Caren H, Kryh H, Martinsson T, et al
PEDIATRIC BLOOD & CANCER 2009;53(5):747-747

mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis
Trager C, Vernby A, Kullman A, Ora I, Kogner P, Kagedal B
INTERNATIONAL JOURNAL OF CANCER 2008;123(12):2849-55

Pterin-dependent tyrosine hydroxylase mRNA is not expressed in human melanocytes or melanoma cells
Kagedal B, Kullman A, Lenner L, Trager C, Kogner P, Farneback M
PIGMENT CELL RESEARCH 2004;17(4):346-51

Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastorna cells in blood and bone marrow
Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B
CLINICAL CHEMISTRY 2003;49(1):104-12

Show all publications